65,437 trials
Psoriasis Vulgaris
Primary: Subjects With 'Controlled Disease' ('Clear'/'Almost Clear' for Subjects w. at Least Moderate Disease at Baseline, 'Clear' for Subjects With Mild Disease at Baseline)…
Infertility
Primary: Number of Pregnancies Achieved Per Menstrual Cycle. — 0; 0 pregnancies per cycle
Anemia
Primary: Percentage of Participants Maintaining Hemoglobin (Hb) Levels Between 11-12 Gram Per Deciliter (g/dL) During Final 2 Months of Study
Prostate Cancer
Primary: Number of Patients With a Partial Response, Progressive Disease, or Stable Disease Based on Prostate-Specific Antigen (PSA) or Measurable Disease — 7; 7; 9 participants
Healthy · Stress
Primary: VAS Insecurity (During) — 56.87; 60.93 mm
Cancer of Prostate · Cancer of the Prostate · Neoplasms, Prostate
Primary: Cumulative CD54+ Cell Count — 1.58 10^9 cells/mL
Asthma
Primary: Treatment Failure — 34; 50; 33 participants
Deep Mycosis
Primary: Number of Participants With Treatment-Related Adverse Events — 1 Participants
Chronic Obstructive Pulmonary Disease
Primary: Part A: Morning Predose (Trough) Forced Expiratory Volume in 1 Second (FEV1) — -0.008; 0.043; 0.064 L — p=0.019
Glaucoma, Primary Open Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye — 22.18; 16.11 mmHg
Idiopathic Hyperbilirubinemia · Neonatal Hyperbilirubinemia · Prematurity
Primary: Total Number of Hours of Required Phototherapy — 72; 61 hours
Melanoma
Primary: Overall Survival — 424; 321 Days — p=0.3873
Pulmonary Valve Stenosis · Pulmonary Valve Insufficiency · Aortic Valve Stenosis
Primary: Hemodynamic Performance — 22.2; 13.5; 21.2; 21.9 mmHg
Head and Neck Squamous Cell Carcinoma
Primary: Percentage of Patients Alive and Free of Progression at 6 Months — 27 percentage of patients
Diabetes Mellitus, Type 2 · Hypertension · Hyperlipidemia
Primary: Primary Effectiveness Outcome - LDL — 57.9; 54.8 percentage of time spent at goal